Skip to main content
Top
Published in: Journal of Neurology 6/2020

01-06-2020 | Myasthenia Gravis | Original Communication

Depression in myasthenia gravis: a heterogeneous and intriguing entity

Authors: Yury V. Gavrilov, Tatjana M. Alekseeva, Olga A. Kreis, Philipp O. Valko, Konrad P. Weber, Yulia Valko

Published in: Journal of Neurology | Issue 6/2020

Login to get access

Abstract

Background

Depressive symptoms in myasthenia gravis (MG) are common, may mimic other disease features, and contribute to misdiagnosis and diagnostic delay. Nevertheless, the clinical determinants of depressive symptoms in MG remain poorly studied, in particular their overlap with fatigue. Moreover, studies in MG have rarely looked at distinct depression phenotypes.

Methods

In 68 consecutive MG patients, we ascertained cognitive-affective and somatic depression with the Beck Depression Inventory (BDI), and also assessed age at disease onset, education, marital state, work ability, sleepiness, fatigue, and treatment modalities. Disease severity was graded according to the Myasthenia Gravis Foundation of America (MGFA) classification.

Results

The prevalence of moderate–severe depression was 20.5%. While depression and fatigue showed large overlap (n = 37, 54.4%), only fatigue increased with disease severity, while BDI scores did not. Thymectomy was independently associated with lower BDI scores, but had no impact on fatigue. Total BDI scores were similar in patients with predominantly cognitive-affective and with predominantly somatic depression. However, ESS correlated only with cognitive-affective BDI, and younger age was independently associated with cognitive-affective BDI. Conversely, female sex and thymectomy were independently associated with somatic BDI.

Conclusions

Depression and fatigue are highly prevalent and largely overlapping comorbidities in MG, but only fatigue increased with disease severity, and only depression was milder in thymectomized patients. Comparative use of BDI subscales in MG reveals distinct depression phenotypes with distinct correlations to other disease features.
Literature
1.
go back to reference Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14(10):1023–1036CrossRefPubMed Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14(10):1023–1036CrossRefPubMed
3.
go back to reference Valko Y, Rosengren SM, Jung HH, Straumann D, Landau K, Weber KP (2016) Ocular vestibular evoked myogenic potentials as a test for myasthenia gravis. Neurology 86:660–668CrossRefPubMed Valko Y, Rosengren SM, Jung HH, Straumann D, Landau K, Weber KP (2016) Ocular vestibular evoked myogenic potentials as a test for myasthenia gravis. Neurology 86:660–668CrossRefPubMed
4.
5.
go back to reference Beghi E, Antozzi C, Batocchi AP, Cornelio F, Cosi V, Evoli A, Lombardi M, Mantegazza R, Monticelli ML, Piccolo G, Tonali P, Trevisan D, Zarrelli M (1991) Prognosis of myasthenia gravis: a multicenter follow-up study of 844 patients. J Neurol Sci 106:213–220CrossRefPubMed Beghi E, Antozzi C, Batocchi AP, Cornelio F, Cosi V, Evoli A, Lombardi M, Mantegazza R, Monticelli ML, Piccolo G, Tonali P, Trevisan D, Zarrelli M (1991) Prognosis of myasthenia gravis: a multicenter follow-up study of 844 patients. J Neurol Sci 106:213–220CrossRefPubMed
6.
go back to reference Kalb B, Matell G, Pirskanen R, Lambe M (2002) Epidemiology of myasthenia gravis: a population-based study in Stockholm, Sweden. Neuroepidemiology 21:221–225CrossRefPubMed Kalb B, Matell G, Pirskanen R, Lambe M (2002) Epidemiology of myasthenia gravis: a population-based study in Stockholm, Sweden. Neuroepidemiology 21:221–225CrossRefPubMed
7.
go back to reference Rohr W (1992) Myasthenia gravis in the frontier of psychiatric diagnosis. Psychiatr Prax 19:157–163PubMed Rohr W (1992) Myasthenia gravis in the frontier of psychiatric diagnosis. Psychiatr Prax 19:157–163PubMed
8.
go back to reference Lázaro E, Amayra I, López-Paz JF, Jometón A, Martín N, Caballero P, De Nicolás L, Hoffmann H, Kessler H, Ruiz B, Martínez O (2013) Facial affect recognition in myasthenia gravis. Span J Psychol 16:E52CrossRefPubMed Lázaro E, Amayra I, López-Paz JF, Jometón A, Martín N, Caballero P, De Nicolás L, Hoffmann H, Kessler H, Ruiz B, Martínez O (2013) Facial affect recognition in myasthenia gravis. Span J Psychol 16:E52CrossRefPubMed
9.
go back to reference Santy PA (1983) Undiagnosed myasthenia gravis in emergency psychiatric referrals. Ann Emerg Med 12:397–398CrossRefPubMed Santy PA (1983) Undiagnosed myasthenia gravis in emergency psychiatric referrals. Ann Emerg Med 12:397–398CrossRefPubMed
10.
go back to reference Shinkai K, Ohmori O, Ueda N, Nakamura J, Amano T, Tsuji S (2001) A case of myasthenia gravis preceded by major depression. J Neuropsychiatr Clin Neurosci 13:116–117CrossRef Shinkai K, Ohmori O, Ueda N, Nakamura J, Amano T, Tsuji S (2001) A case of myasthenia gravis preceded by major depression. J Neuropsychiatr Clin Neurosci 13:116–117CrossRef
11.
go back to reference Rüegg SJ, Dirnhofer S, Buitrago-Tellez CH, Steck AJ, Marsch S (2007) Life-threatening myasthenia gravis masked by a psychiatric disorder. Swiss Arch Neurol Psychiatry 158:150–154CrossRef Rüegg SJ, Dirnhofer S, Buitrago-Tellez CH, Steck AJ, Marsch S (2007) Life-threatening myasthenia gravis masked by a psychiatric disorder. Swiss Arch Neurol Psychiatry 158:150–154CrossRef
12.
go back to reference Okamoto N, Furusawa Y, Sakamoto K, Yamamoto T, Kondo Y, Nagafusa Y, Higuchi T (2010) Major depression: what caused the crisis? The Lancet 375:346CrossRef Okamoto N, Furusawa Y, Sakamoto K, Yamamoto T, Kondo Y, Nagafusa Y, Higuchi T (2010) Major depression: what caused the crisis? The Lancet 375:346CrossRef
13.
go back to reference Kulaksizoglu IB (2007) Mood and anxiety disorders in patients with myasthenia gravis; aetiology, diagnosis and treatment. CNS Drugs 21:473–481CrossRefPubMed Kulaksizoglu IB (2007) Mood and anxiety disorders in patients with myasthenia gravis; aetiology, diagnosis and treatment. CNS Drugs 21:473–481CrossRefPubMed
14.
go back to reference Meyer E (1966) Psychological disturbances in myasthenia gravis: a predictive study. Ann N Y Acad Sci 135:417–423CrossRefPubMed Meyer E (1966) Psychological disturbances in myasthenia gravis: a predictive study. Ann N Y Acad Sci 135:417–423CrossRefPubMed
15.
go back to reference Doering S, Henze T, Schussler G (1993) Coping with myasthenia gravis and implications for psychotherapy. Arch Neurol 50:617–620CrossRefPubMed Doering S, Henze T, Schussler G (1993) Coping with myasthenia gravis and implications for psychotherapy. Arch Neurol 50:617–620CrossRefPubMed
16.
go back to reference Eliasen A, Dalhoff KP, Horwitz H (2018) Neurological diseases and risk of suicide attempt: a case-control study. J Neurol 265:1303–1309CrossRefPubMed Eliasen A, Dalhoff KP, Horwitz H (2018) Neurological diseases and risk of suicide attempt: a case-control study. J Neurol 265:1303–1309CrossRefPubMed
17.
go back to reference Tran C, Bril V, Katzberg HD, Barnett C (2018) Fatigue is a relevant outcome in patients with myasthenia gravis. Muscle Nerve 58:197–203CrossRefPubMed Tran C, Bril V, Katzberg HD, Barnett C (2018) Fatigue is a relevant outcome in patients with myasthenia gravis. Muscle Nerve 58:197–203CrossRefPubMed
18.
go back to reference Alekseeva TM, Gavrilov YV, Kreis OA, Valko PO, Weber KP, Valko Y (2018) Fatigue in patients with myasthenia gravis. J Neurol 265:2312–2321CrossRefPubMed Alekseeva TM, Gavrilov YV, Kreis OA, Valko PO, Weber KP, Valko Y (2018) Fatigue in patients with myasthenia gravis. J Neurol 265:2312–2321CrossRefPubMed
19.
go back to reference Paul RH, Cohen RA, Goldstein JM, Gilchrist JM (2000) Severity of mood, self-evaluative, and vegetative symptoms of depression in myasthenia gravis. J Neuropsychiatr Clin Neurosci 12:499–501CrossRef Paul RH, Cohen RA, Goldstein JM, Gilchrist JM (2000) Severity of mood, self-evaluative, and vegetative symptoms of depression in myasthenia gravis. J Neuropsychiatr Clin Neurosci 12:499–501CrossRef
20.
go back to reference Glennerster A, Palace J, Warburton D, Oxbury S, Newsom-Davis J (1996) Memory in myasthenia gravis: neuropsychological tests of central cholinergic function before and after effective immunologic treatment. Neurology 46:1138–1142CrossRefPubMed Glennerster A, Palace J, Warburton D, Oxbury S, Newsom-Davis J (1996) Memory in myasthenia gravis: neuropsychological tests of central cholinergic function before and after effective immunologic treatment. Neurology 46:1138–1142CrossRefPubMed
21.
go back to reference Fisher J, Parkinson K, Kothari MJ (2003) Self-reported depressive symptoms in myasthenia gravis. J Clin Neuromuscul Dis 4:105–108CrossRefPubMed Fisher J, Parkinson K, Kothari MJ (2003) Self-reported depressive symptoms in myasthenia gravis. J Clin Neuromuscul Dis 4:105–108CrossRefPubMed
22.
go back to reference Suzuki Y, Utsugisawa K, Suzuki S, Nagane Y, Masuda M, Kabasawa C, Shimizu Y, Utsumi H, Uchiyama S, Fujihara K, Suzuki N (2011) Factors associated with depressive state in patients with myasthenia gravis: a multicentre cross-sectional study. BMJ Open 1:e000313PubMedCentralCrossRefPubMed Suzuki Y, Utsugisawa K, Suzuki S, Nagane Y, Masuda M, Kabasawa C, Shimizu Y, Utsumi H, Uchiyama S, Fujihara K, Suzuki N (2011) Factors associated with depressive state in patients with myasthenia gravis: a multicentre cross-sectional study. BMJ Open 1:e000313PubMedCentralCrossRefPubMed
23.
go back to reference Aysal F, Karamustafalioğlu O, Özçelik B, Yilmaz M, Karamustafalioğlu N, Yumrukçal H, Tankaya O (2013) The relationship of symptoms of anxiety and depression with disease severity and treatment modality in myasthenia gravis: a cross-sectional study. Arch Neuropsychiatr 50:295–300CrossRef Aysal F, Karamustafalioğlu O, Özçelik B, Yilmaz M, Karamustafalioğlu N, Yumrukçal H, Tankaya O (2013) The relationship of symptoms of anxiety and depression with disease severity and treatment modality in myasthenia gravis: a cross-sectional study. Arch Neuropsychiatr 50:295–300CrossRef
24.
go back to reference Alekseeva TM, Kreis OA, Gavrilov YV, Valko PO, Weber KP, Valko Y (2019) Impact of autoimmune comorbidity on fatigue, sleepiness and mood in myasthenia gravis. J Neurol 266:2027–2034CrossRefPubMed Alekseeva TM, Kreis OA, Gavrilov YV, Valko PO, Weber KP, Valko Y (2019) Impact of autoimmune comorbidity on fatigue, sleepiness and mood in myasthenia gravis. J Neurol 266:2027–2034CrossRefPubMed
25.
go back to reference Alekseeva TM, Kosachev VD, Khalmurzina AN (2016) Clinical and immunological features and treatment of myasthenia gravis in the elderly (review). Neuromuscul Dis 6:10–16CrossRef Alekseeva TM, Kosachev VD, Khalmurzina AN (2016) Clinical and immunological features and treatment of myasthenia gravis in the elderly (review). Neuromuscul Dis 6:10–16CrossRef
26.
go back to reference Kosachev VD, Lobzin SV, Alekseeva TM, Kreis OA (2015) Clinical and neurological criteria for the diagnosis of myasthenia gravis. Herald of the Northwestern State Medical University named after I.I. Mechnikov 7:102–107 Kosachev VD, Lobzin SV, Alekseeva TM, Kreis OA (2015) Clinical and neurological criteria for the diagnosis of myasthenia gravis. Herald of the Northwestern State Medical University named after I.I. Mechnikov 7:102–107
28.
go back to reference Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561–571CrossRefPubMed Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561–571CrossRefPubMed
29.
go back to reference Andriushchenko AV, Drobizhev MIu, Dobrovol'skiĭ AV (2003) A comparative validation of the scale CES-D, BDI, and HADS(d) in diagnosis of depressive disorders in general practice. Zhurnal Nevrologii i Psikhiatrii imeni S.S Korsakova 103:11–18PubMed Andriushchenko AV, Drobizhev MIu, Dobrovol'skiĭ AV (2003) A comparative validation of the scale CES-D, BDI, and HADS(d) in diagnosis of depressive disorders in general practice. Zhurnal Nevrologii i Psikhiatrii imeni S.S Korsakova 103:11–18PubMed
30.
go back to reference Visser M, Leentjens AF, Marinus J, Stiggelbout AM, van Hilten JJ (2006) Reliability and validity of the Beck depression inventory in patients with Parkinson’s disease. Mov Disord 21:668–672CrossRefPubMed Visser M, Leentjens AF, Marinus J, Stiggelbout AM, van Hilten JJ (2006) Reliability and validity of the Beck depression inventory in patients with Parkinson’s disease. Mov Disord 21:668–672CrossRefPubMed
31.
go back to reference Berg A, Lönnqvist J, Palomäki H, Kaste M (2009) Assessment of depression after stroke: a comparison of different screening instruments. Stroke 40:523–529CrossRefPubMed Berg A, Lönnqvist J, Palomäki H, Kaste M (2009) Assessment of depression after stroke: a comparison of different screening instruments. Stroke 40:523–529CrossRefPubMed
32.
go back to reference Sacco R, Santangelo G, Stamenova S, Bisecco A, Bonavita S, Lavorgna L, Trojano L, D’Ambrosio A, Tedeschi G, Gallo A (2016) Psychometric properties and validity of Beck Depression Inventory II in multiple sclerosis. Eur J Neurol 23:744–750CrossRefPubMed Sacco R, Santangelo G, Stamenova S, Bisecco A, Bonavita S, Lavorgna L, Trojano L, D’Ambrosio A, Tedeschi G, Gallo A (2016) Psychometric properties and validity of Beck Depression Inventory II in multiple sclerosis. Eur J Neurol 23:744–750CrossRefPubMed
33.
go back to reference Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121–1123CrossRefPubMed Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121–1123CrossRefPubMed
34.
35.
go back to reference Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF (1994) Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 18:S79–83CrossRefPubMed Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF (1994) Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 18:S79–83CrossRefPubMed
36.
go back to reference Gavrilov YV, Shkilnyuk GG, Valko PO, Stolyarov ID, Ivashkova EV, Ilves AG, Nikiforova IG, Shchelkova OY, Vasserman LI, Vais EE, Valko Y (2018) Validation of the Russian version of the fatigue impact scale and fatigue severity scale in multiple sclerosis patients. Acta Neurol Scand 138:408–416CrossRefPubMed Gavrilov YV, Shkilnyuk GG, Valko PO, Stolyarov ID, Ivashkova EV, Ilves AG, Nikiforova IG, Shchelkova OY, Vasserman LI, Vais EE, Valko Y (2018) Validation of the Russian version of the fatigue impact scale and fatigue severity scale in multiple sclerosis patients. Acta Neurol Scand 138:408–416CrossRefPubMed
37.
go back to reference Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14(6):540–545CrossRefPubMed Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14(6):540–545CrossRefPubMed
38.
go back to reference Bogdan A, Barnett C, Ali A, Al Qwaifly M, Abraham A, Mannan S, Ng E, Bril V (2019) Chronic stress, depression and personality type in patients with myasthenia gravis. Eur J Neurol 27(1):204–209CrossRefPubMed Bogdan A, Barnett C, Ali A, Al Qwaifly M, Abraham A, Mannan S, Ng E, Bril V (2019) Chronic stress, depression and personality type in patients with myasthenia gravis. Eur J Neurol 27(1):204–209CrossRefPubMed
39.
go back to reference Nagane Y, Murai H, Imai T, Yamamoto D, Tsuda E, Minami N, Suzuki Y, Kanai T, Uzawa A, Kawaguchi N, Masuda M, Konno S, Suzuki H, Aoki M, Utsugisawa K (2017) Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study. BMJ Open 7:e013278PubMedCentralCrossRefPubMed Nagane Y, Murai H, Imai T, Yamamoto D, Tsuda E, Minami N, Suzuki Y, Kanai T, Uzawa A, Kawaguchi N, Masuda M, Konno S, Suzuki H, Aoki M, Utsugisawa K (2017) Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study. BMJ Open 7:e013278PubMedCentralCrossRefPubMed
40.
go back to reference Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9:46–56PubMedCentralCrossRefPubMed Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9:46–56PubMedCentralCrossRefPubMed
41.
42.
go back to reference Kim YK, Na KS, Shin KH, Jung HY, Choi SH, Kim JB (2007) Cytokine imbalance in the pathophysiology of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 31:1044–1053CrossRefPubMed Kim YK, Na KS, Shin KH, Jung HY, Choi SH, Kim JB (2007) Cytokine imbalance in the pathophysiology of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 31:1044–1053CrossRefPubMed
43.
go back to reference Sukoff Rizzo SJ, Neal SJ, Hughes ZA, Beyna M, Rosenzweig-Lipson S, Moss SJ, Brandon NJ (2012) Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like phenotypes. Trans Psychiatry 2:e199CrossRef Sukoff Rizzo SJ, Neal SJ, Hughes ZA, Beyna M, Rosenzweig-Lipson S, Moss SJ, Brandon NJ (2012) Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like phenotypes. Trans Psychiatry 2:e199CrossRef
44.
45.
go back to reference Twork S, Wiesmeth S, Klewer J, Pöhlau D, Kugler J (2010) Quality of life and life circumstances in German myasthenia gravis patients. Health Qual Life Outcomes 8:129PubMedCentralCrossRefPubMed Twork S, Wiesmeth S, Klewer J, Pöhlau D, Kugler J (2010) Quality of life and life circumstances in German myasthenia gravis patients. Health Qual Life Outcomes 8:129PubMedCentralCrossRefPubMed
46.
go back to reference Basta IZ, Pekmezović TD, Perić SZ, Kisić-Tepavčević DB, Rakočević-Stojanović VM, Stević ZD, Lavrnić DV (2012) Assessment of health-related quality of life in patients with myasthenia gravis in Belgrade (Serbia). Neurol Sci 33:1375–1381CrossRefPubMed Basta IZ, Pekmezović TD, Perić SZ, Kisić-Tepavčević DB, Rakočević-Stojanović VM, Stević ZD, Lavrnić DV (2012) Assessment of health-related quality of life in patients with myasthenia gravis in Belgrade (Serbia). Neurol Sci 33:1375–1381CrossRefPubMed
47.
go back to reference Blum S, Lee D, Gillis D, McEniery DF, Reddel S, McCombe P (2015) Clinical features and impact of myasthenia gravis disease in Australian patients. J Clin Neurosci 22:1164–1169CrossRefPubMed Blum S, Lee D, Gillis D, McEniery DF, Reddel S, McCombe P (2015) Clinical features and impact of myasthenia gravis disease in Australian patients. J Clin Neurosci 22:1164–1169CrossRefPubMed
48.
go back to reference Braz NFT, Rocha NP, Vieira ÉLM, Barbosa IG, Gomez RS, Kakehasi AM, Teixeira AL (2018) Muscle strength and psychiatric symptoms influence health-related quality of life in patients with myasthenia gravis. J Clin Neurosci 50:41–44CrossRefPubMed Braz NFT, Rocha NP, Vieira ÉLM, Barbosa IG, Gomez RS, Kakehasi AM, Teixeira AL (2018) Muscle strength and psychiatric symptoms influence health-related quality of life in patients with myasthenia gravis. J Clin Neurosci 50:41–44CrossRefPubMed
49.
go back to reference Jeong A, Min JH, Kang YK, Kim J, Choi M, Seok JM, Kim BJ (2018) Factors associated with quality of life of people with Myasthenia Gravis. PLoS ONE 13:e0206754PubMedCentralCrossRefPubMed Jeong A, Min JH, Kang YK, Kim J, Choi M, Seok JM, Kim BJ (2018) Factors associated with quality of life of people with Myasthenia Gravis. PLoS ONE 13:e0206754PubMedCentralCrossRefPubMed
50.
go back to reference Alanazy MH, Binabbad RS, Alromaih NI, Almansour RA, Alanazi SN, Alhamdi MF, Alazwary N, Muayqil T (2019) Severity and depression can impact quality of life in patients with myasthenia gravis. Muscle Nerve 61(1):69–73CrossRefPubMed Alanazy MH, Binabbad RS, Alromaih NI, Almansour RA, Alanazi SN, Alhamdi MF, Alazwary N, Muayqil T (2019) Severity and depression can impact quality of life in patients with myasthenia gravis. Muscle Nerve 61(1):69–73CrossRefPubMed
51.
go back to reference Magni G, Micaglio GF, Lalli R, Bejato L, Candeago MR, Merskey H, Angelini C (1988) Psychiatric disturbances associated with myasthenia gravis. Acta Psychiatr ScandScandinavica 77:443e5 Magni G, Micaglio GF, Lalli R, Bejato L, Candeago MR, Merskey H, Angelini C (1988) Psychiatric disturbances associated with myasthenia gravis. Acta Psychiatr ScandScandinavica 77:443e5
52.
go back to reference Leach LS, Christensen H, Mackinnon AJ, Windsor TD, Butterworth P (2008) Gender differences in depression and anxiety across the adult lifespan: the role of psychosocial mediators. Soc Psychiatry Psychiatr Epidemiol 43:983–998CrossRefPubMed Leach LS, Christensen H, Mackinnon AJ, Windsor TD, Butterworth P (2008) Gender differences in depression and anxiety across the adult lifespan: the role of psychosocial mediators. Soc Psychiatry Psychiatr Epidemiol 43:983–998CrossRefPubMed
Metadata
Title
Depression in myasthenia gravis: a heterogeneous and intriguing entity
Authors
Yury V. Gavrilov
Tatjana M. Alekseeva
Olga A. Kreis
Philipp O. Valko
Konrad P. Weber
Yulia Valko
Publication date
01-06-2020
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 6/2020
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-020-09767-7

Other articles of this Issue 6/2020

Journal of Neurology 6/2020 Go to the issue